ACHV Stock Summary and Trading Ideas (Achieve Life Sciences - Common Shares | NASDAQ:ACHV)

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Achieve Life Sciences - Common Shares trades on the NASDAQ stock market under the symbol ACHV.

As of April 2, 2026, ACHV stock price climbed to $3.23 with 462,158 million shares trading.

ACHV has a beta of 2.75, meaning it tends to be more sensitive to market movements. ACHV has a correlation of 0.22 to the broad based SPY ETF.

ACHV has a market cap of $171.95 million. This is considered a Micro Cap stock.

In the last 3 years, ACHV traded as high as $10.30 and as low as $1.84.

The top ETF exchange traded funds that ACHV belongs to (by Net Assets): VTI, VXF, IWC, DFMC, AVTM.

ACHV has outperformed the market in the last year with a return of +26.7%, while the SPY ETF gained +17.5%. However, in the most recent history, ACHV shares have underperformed the stock market with its stock returning -35.0% in the last 3 month period and -21.0% for the last 2 week period, while SPY has returned -3.7% and -0.1%, respectively.

ACHV support price is $2.99 and resistance is $3.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACHV shares will trade within this expected range on the day.